EVE Health Group Limited (AU:EVE) has released an update.
EVE Health Group Limited has reported a robust quarter with its subsidiary, Meluka Australia, marking a 21% revenue increase and a tenth consecutive quarter of growth, thanks in part to its popular P3 Gut Builder product. The company has also successfully sold its Jendale tea tree property for $800,000 and is finalizing the sale of another property, with plans to reinvest in complementary acquisitions to enhance growth. Financially, the company showed a steady cash flow with reduced operating costs and a focus on divesting non-core assets to concentrate on its health and wellness segment.
For further insights into AU:EVE stock, check out TipRanks’ Stock Analysis page.
